A clinical trial update dated September 3, 2026 reports that the study titled "A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use" has been marked as terminated.
The trial, registered as NCT03145857, was listed as Phase 1/Phase 2. It involved the use of [68]Ga-HA-DOTATATE in relation to somatostatin receptor-related tumor identification, a pathway relevant to octreotide, which is an approved somatostatin analog.
The registry entry states the trial status as terminated but does not provide a stated reason for termination in the data available. No results, efficacy findings, or safety conclusions were included in this update. The record reflects only a change in trial status as of the date given.
Readers should note that this update pertains to a study status change and does not represent new clinical findings or a change in the regulatory status of octreotide itself, which remains approved.
For more background on this compound, see the octreotide overview page.